Previous 10 | Next 10 |
NEW YORK, Jan. 13, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders...
Cantor Fitzgerald has started the coverage on Brooklyn ImmunoTherapeutics (BTX -2.9%) with an Overweight recommendation arguing that the company could attract a partnership for its experimental cancer therapy IRX-2. IRX‑2, a mixed, human-derived cytokine product, is currently undergoin...
NEW YORK, Dec. 17, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, ...
Brooklyn ImmunoTherapeutics (NASDAQ:BTX) jumps 3.58% pre-market on being added to the Nasdaq Biotech Index, effective December 20, 2021. Brooklyn joins 128 other companies on the index, as 21 companies were removed. For further details see: Brooklyn Immunotherap...
NEW YORK, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, ...
NEW YORK, Dec. 02, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, ...
NEW YORK, Nov. 29, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with cancer, blood disorders, ...
Brooklyn ImmunoTherapeutics (NASDAQ:BTX) has filed with the SEC a registration statement on Form S-1 relating to the proposed public offering of up to 6,281,454 shares of common stock by certain selling stockholders in connection with its acquisition of Novellus in July 2021. Shares down...
NEW YORK, Nov. 19, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”) today announced that on November 18, 2021 it filed with the Securities and Exchange Commission a registration statement on Form S-1 relating to the proposed public offering...
Brooklyn Immunotherapeutics (NASDAQ:BTX): Q3 GAAP EPS of -$1.70 misses by $1.62. Cash of $24.4M. Press Release For further details see: Brooklyn Immunotherapeutics EPS misses by $1.62
News, Short Squeeze, Breakout and More Instantly...
Brooklyn ImmunoTherapeutics Inc. Company Name:
BTX Stock Symbol:
NYSE Market:
Brooklyn ImmunoTherapeutics Inc. Website:
New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize the potential of cell engineering to provide patients with transformational new medicines Company’s...
SAN DIEGO, July 26, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”) today announces results from the INSPIRE phase 2 trial of IRX-2, a multi-cytokine biologic immunotherapy, in patients with newly diagnos...
SAN DIEGO, June 17, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on developing advanced therapies using state-of-the-art mRNA cell engineering technology, today ann...